DE602006016567D1 - Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs - Google Patents

Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs

Info

Publication number
DE602006016567D1
DE602006016567D1 DE602006016567T DE602006016567T DE602006016567D1 DE 602006016567 D1 DE602006016567 D1 DE 602006016567D1 DE 602006016567 T DE602006016567 T DE 602006016567T DE 602006016567 T DE602006016567 T DE 602006016567T DE 602006016567 D1 DE602006016567 D1 DE 602006016567D1
Authority
DE
Germany
Prior art keywords
reagents
cancer
treatment
methods
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016567T
Other languages
English (en)
Inventor
Brian Z Ring
Douglas T Ross
Robert S Seitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarient Diagnostic Services Inc
Original Assignee
Applied Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genomics Inc filed Critical Applied Genomics Inc
Publication of DE602006016567D1 publication Critical patent/DE602006016567D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602006016567T 2005-02-18 2006-02-17 Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs Active DE602006016567D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/061,067 US20060003391A1 (en) 2003-08-11 2005-02-18 Reagents and methods for use in cancer diagnosis, classification and therapy
PCT/US2006/005601 WO2006132683A2 (en) 2005-02-18 2006-02-17 Reagents and methods for use in cancer diagnosis, classification and therapy

Publications (1)

Publication Number Publication Date
DE602006016567D1 true DE602006016567D1 (de) 2010-10-14

Family

ID=37064199

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016567T Active DE602006016567D1 (de) 2005-02-18 2006-02-17 Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs

Country Status (8)

Country Link
US (1) US20060003391A1 (de)
EP (1) EP1856535B1 (de)
AT (1) ATE479898T1 (de)
AU (1) AU2006255766B2 (de)
CA (1) CA2598170C (de)
DE (1) DE602006016567D1 (de)
ES (1) ES2351938T3 (de)
WO (1) WO2006132683A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
WO2005098450A2 (en) * 2004-04-02 2005-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in evaluating and treating neoplastic disease conditions
US8748445B2 (en) * 2004-10-27 2014-06-10 The Uab Research Foundation Methods for treating glioma
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US8697373B2 (en) 2006-10-06 2014-04-15 Clarient Diagnostic Services, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2763537T3 (es) * 2008-09-16 2020-05-29 Beckman Coulter Inc Diagrama de árbol interactivo para datos de citometría de flujo
JP5951498B2 (ja) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
US10627412B2 (en) 2010-03-17 2020-04-21 Kagoshima University Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same
WO2013007640A1 (en) * 2011-07-08 2013-01-17 Centre Leon Berard Pla2r1 as anti-tumoral compound and as biomarker for the detection of cancer
PE20142168A1 (es) 2012-01-27 2015-01-17 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
EP4269427A3 (de) * 2016-05-27 2023-11-22 Synthex, Inc. Proteinschnittstellen
US10889543B2 (en) * 2016-11-20 2021-01-12 The Board Of Regents Of The University Of Texas System Fine-tune modulators of neuronal excitability for neuropsychiatric disorders
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598811A (en) * 1977-01-12 1981-09-23 Hoffmann La Roche Carcinoma-associated antigens
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4666845A (en) * 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4657851A (en) * 1984-01-03 1987-04-14 Georgetown University Breast cancer diagnostic blood test
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
US4803169A (en) * 1986-02-05 1989-02-07 Cetus Corporation Assay for human breast cancer
US5843684A (en) * 1990-06-27 1998-12-01 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes
US6322989B1 (en) * 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US5593847A (en) * 1991-12-30 1997-01-14 Bayer Corporation Monitoring of NC 50/90 in blood samples of breast cancer patients
US5965362A (en) * 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US6288039B1 (en) * 1995-03-07 2001-09-11 George Washington University Pharmaceutical compositions methods and kits for treatment and diagnosis of breast cancer
JP2751886B2 (ja) * 1995-04-02 1998-05-18 ダイキン工業株式会社 乳ガン細胞の検出方法
EP0951541B1 (de) * 1995-07-31 2005-11-30 Urocor, Inc. Biomarker und ziele für die diagnose, prognose und handhabung von prostatkrebs
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US20040073016A1 (en) * 1996-01-11 2004-04-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US5983211A (en) * 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
JP2001503276A (ja) * 1996-11-07 2001-03-13 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 乳癌の易罹病性の診断アッセイ
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
US5840507A (en) * 1997-03-19 1998-11-24 Oncotech, Inc. Methods for cancer prognosis and diagnosis
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
JP2001523096A (ja) * 1997-03-21 2001-11-20 エム ユー エス シー ファンデーション フォーリサーチ ディベロップメント 乳癌の診断および治療のための方法ならびに組成物
WO1998059073A1 (en) * 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
US6063586A (en) * 1997-09-03 2000-05-16 Eye & Ear Foundation Diagnostic protocol
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US6730477B1 (en) * 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US20030039959A1 (en) * 1998-10-02 2003-02-27 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US20030124543A1 (en) * 1999-01-15 2003-07-03 Stuart Susan G. Breast cancer marker
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6649342B1 (en) * 1999-03-15 2003-11-18 Eos Biotechnology, Inc. Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US6762020B1 (en) * 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
AU6583700A (en) * 1999-08-13 2001-03-13 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
US6544742B1 (en) * 1999-09-03 2003-04-08 Incyte Genomics, Inc. Detection of genes regulated by EGF in breast cancer
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
US6780586B1 (en) * 1999-11-29 2004-08-24 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20020146727A1 (en) * 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US20030198951A1 (en) * 1999-12-02 2003-10-23 David Mack Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US20040146862A1 (en) * 2000-03-15 2004-07-29 Eos Biotechnology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030170631A1 (en) * 2000-04-03 2003-09-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US20020009738A1 (en) * 2000-04-03 2002-01-24 Houghton Raymond L. Methods, compositions and kits for the detection and monitoring of breast cancer
US20020068691A1 (en) * 2000-06-21 2002-06-06 Susana Salceda Method of diagnosing, monitoring, staging, imaging and treating breast cancer
AU2002224558A1 (en) * 2000-07-11 2002-02-05 The Regents Of The University Of California Method of diagnosing breast cancer using nipple fluid
US6631330B1 (en) * 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
US20020068036A1 (en) * 2000-10-13 2002-06-06 Eos Biotechnology, Inc. Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20020182621A1 (en) * 2001-01-25 2002-12-05 Max Costa Methods and compositions using cap43 proteins and nucleic acids to diagnose and treat cancer and other disorders
WO2002064798A1 (en) * 2001-02-12 2002-08-22 Bionomics Limited Dna sequences differentially expressed in tumour cell lines
US7056663B2 (en) * 2001-03-23 2006-06-06 California Pacific Medical Center Prognostic methods for breast cancer
EP1380840A4 (de) * 2001-03-27 2005-08-17 Teikoku Hormone Mfg Co Ltd Diagnoseverfahren für brustkrebs
US20050065333A1 (en) * 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
BR0209646A (pt) * 2001-05-16 2006-10-10 Novartis Ag genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
CA2451074C (en) * 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP1453977B1 (de) * 2001-08-16 2009-11-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Molekulare eigenschaften von nichtkleinzelligem lungenkrebs
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US7504222B2 (en) * 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US7053663B2 (en) * 2002-03-26 2006-05-30 Intel Corporation Dynamic gate with conditional keeper for soft error rate reduction
US20050176072A1 (en) * 2002-06-21 2005-08-11 Martin Michelle D. MTA1 is a predictive and prognostic factor in human breast cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1604014A4 (de) * 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc Genexpression bei brustkrebs
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
CA2524708C (en) * 2003-06-06 2009-10-06 F. Hoffmann-La Roche Ag Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
CA2531967C (en) * 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
WO2005040804A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein spee as a marker for breast cancer
ES2377407T3 (es) * 2003-10-15 2012-03-27 F. Hoffmann-La Roche Ag Utilización de la proteína ASC como marcador para cáncer de seno
WO2005040812A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein ubc13 as a marker for breast cancer
US7981618B2 (en) * 2003-11-05 2011-07-19 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
EP1774025A4 (de) * 2004-07-09 2009-09-16 Univ Pittsburgh Identifizierung von markern bei lungen- und brustkrebs
EP1800130B1 (de) * 2004-09-22 2011-08-17 Tripath Imaging, Inc. Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose

Also Published As

Publication number Publication date
ATE479898T1 (de) 2010-09-15
US20060003391A1 (en) 2006-01-05
EP1856535A2 (de) 2007-11-21
AU2006255766B2 (en) 2013-03-28
AU2006255766A1 (en) 2006-12-14
WO2006132683A3 (en) 2007-04-05
WO2006132683A2 (en) 2006-12-14
ES2351938T3 (es) 2011-02-14
CA2598170C (en) 2012-10-02
EP1856535B1 (de) 2010-09-01
CA2598170A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
DE602006016567D1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
HK1131806A1 (en) Biomarkers for prostate cancer and methods using the same
Torphy et al. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
EP4293358A3 (de) Flüchtige organische verbindungen als krebs biomarker
MX2022002244A (es) Metodo para identificar respondedores a degradantes de smarca2/4.
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
ATE479778T1 (de) Verfahren zur diagnose nicht-kleinzelliger lungenkarzinome über die trna-dihydrouridin- synthaseaktivität von urlc8
WO2005083118A3 (en) Pin-prc transition genes
EP1896849A4 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
Tam et al. Neoadjuvant chemotherapy in local‐regionally advanced nasopharyngeal carcinoma: a National Cancer Database analysis
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
ATE530668T1 (de) Verfahren und kits zur brustkrebsprognose
WO2008043104A3 (en) Reagents and methods for use in cancer diagnosis, classification and therapy
Fossum et al. Role of Ki-67, MRE11, and PD-L1 as predictive biomarkers for recurrence pattern in muscle-invasive bladder cancer

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1856535

Country of ref document: EP

Representative=s name: LEINWEBER & ZIMMERMANN, DE

R081 Change of applicant/patentee

Ref document number: 1856535

Country of ref document: EP

Owner name: CLARIENT DIAGNOSTIC SERVICES, INC., US

Free format text: FORMER OWNER: APPLIED GENOMICS, INC., HUNTSVILLE, US

Effective date: 20120814

R082 Change of representative

Ref document number: 1856535

Country of ref document: EP

Representative=s name: LEINWEBER & ZIMMERMANN, DE

Effective date: 20120814